Case #1724.0

Placebo Trials in Africa: The African American Dilemma at the Centers for Disease Control

Publication Date: January 01, 2004
$3.95
Current Stock:

Educator Access

A review copy of this case is available free of charge to educators and trainers. Please create an account or sign in to gain access to this material.

Permission to Reprint

Each purchase of this product entitles the buyer to one digital file and use. If you intend to distribute, teach, or share this item, you must purchase permission for each individual who will be given access. Learn more about purchasing permission to reprint.

Abstract:
In 1997, a small group of African American doctors and scientists on the staff of the Centers for Disease Control and Prevention (CDC) found themselves on the horns of a painful dilemma. For months, they had been making known their objections to clinical trials the CDC was sponsoring in Africa. The trials sought to reduce the rate of mother-to-infant transmission of the human immunodeficiency virus (HIV), the virus that causes AIDS, through short courses of treatment with the drug Zidovudine (AZT). While applauding the goal of the studies which, if successful, could potentially save the lives of millions of African newborns at risk of infection, the members of the group were troubled by the means to that end: placebo-controlled trials in which some mothers would be given no treatment at all. Because studies in the US and elsewhere had already shown that a longer course of treatment with AZT was effective in cutting HIV transmission rates, they argued, it was unnecessary, and unethical, to have a control group that would go untreated. The group had brought their concerns to the leadership of CDC; but while they had been granted a respectful hearing, they had not succeeded in altering the design of the clinical trials. Now, they faced the choice of making their objections public or acquiescing to the trials. Taking the latter course would, for them, raise the specter of complicity in the kind of research in which African Americans themselves had once been the victims, in a notorious study of syphilis. But taking the former course would bring them into open conflict with two prominent and respected officials in CDC, themselves African American and one of them, David Satcher, head of the agency and a rising star in the Clinton administration. Public sparring over ethical issues could be crippling to Satcher and compromise his chance of being named to the post of Surgeon General. With the clock ticking on the clinical trials, the group debated among themselves about how, or whether, they should proceed.

Learning Objective:
This case can be used to explore the often-subtle dynamics that racial identity issues can create in the workplace and places them in a context of a professional ethics decision.

Other Details

Case Author:
Kimberlee Wyche, Luc Joseph, Joan Reede
Pages (incl. exhibits):
8
Setting:
Africa
Language:
English
Funding Source:
Commonwealth Fund; Robert Wood Johnson Foundation